To Evaluate Safety and Efficacy of a Radiofrequency Renal Denervation System in Treatment of Essential Hypertension

Inclusion Criteria: 1. Subject with age of 18 to 65 years old (include 65), male or female; 2. Subject with essential hypertension who has an office BP of ≥150/90mmHg and \<180/110 mmHg (both SBP and DBP meet the criteria), and an average SBP of ≥ 135mmHg measured by 24-hour ABPM, after taking ≥ 2 antihypertensive medications for ≥ 4 weeks; 3. Subject with the resting heart rate ≥70bpm, if not taking beta-blockers (this criterion does not apply to those taking beta-blockers); 4. Subject with confirmed diagnosis of essential hypertension; 5. Subject with or without accessary renal arteries; 6. Subject who has signed the informed consent form, agrees to participate in this clinical trial, and is willing to comply with the required follow-ups per the trial protocol. Exclusion Criteria: 1. Subject who is pregnant, nursing or planning to become pregnant during the study; 2. Subject with the shape and structure of unilateral or bilateral renal artery that are not suitable for ablation procedure (renal artery stenosis more than 50%, renal aneurysm, renal artery abnormality, renal artery diameter \<4mm or treatable segment length \<20mm); 3. Subject who has unilateral kidney or kidney transplant; 4. Subject with a history of renal artery interventional therapy or renal denervation; 5. Subject with any conditions that may affect the accuracy of blood pressure measurement: such as the diameter of the upper arm is too large relative to the cuff, arrhythmia; 6. Subject with secondary hypertension; 7. Subject with pseudo-hypertension; 8. Subject with orthostatic hypotension; 9. Subject with eGFR \<45mL/min/l.73m2; 10. Subject with average SBP is \< 135mmHg on 24-hour ABPM; 11. Subject with a history of hospitalization for hypertensive emergency within past one year; 12. Subject with type I diabetes mellitus; 13. Subject with primary pulmonary hypertension; 14. Subject with a history of bleeding diathesis and hematological disorders; 15. Subject with a history of embolism within past 6 months; 16. Subject with a history of acute coronary syndrome within past 6 months; 17. Subject with a history of ventricular fibrillation, polymorphic ventricular tachycardia within past 6 months; 18. Subject with serum HIV-positive; 19. Subject who is allergic to contrast agents; 20. Subject with mental illness or any psychological problems that may interfere with the participating in the study; 21. Subject with a history of stroke or transient ischemic attack (TIA) within past 3 months; 22. Subject with malignant tumors or end-stage disease; 23. Subject with severe peripheral vascular disease or abdominal aortic aneurysm; 24. Subject with severe heart valve stenosis; 25. Subject with cardiac insufficiency (NYHA class III\~IV); 26. Subject with hyperthyroidism or hypothyroidism; 27. Subject with severe electrolyte or liver function abnormalities; 28. Subject who requires mechanical ventilation other than nocturnal respiratory support for sleep apnea; 29. Subject with acute or severe systemic infection; 30. Subject with a history of pacemaker implantation; 31. Subject with a history of major surgery or trauma within 30 days prior to enrollment; 32. Subject who has planned surgery or cardiovascular intervention within the next 6 months; 33. Subject who is participating in other drug or medical device clinical trials; 34. Subject who has known drug or alcohol dependence, difficulty to understand the trial protocol, inability/unwillingness to follow the trial protocol; 35. Subject who is unsuitable for participating in this study in the opinion of investigators;